. Author manuscript; available in PMC: 2022 Jul 5.

Published in final edited form as: Thromb Haemost. 2022 Jan 7;122(6):998–1005. doi: 10.1055/s-0041-1740180

Table 2.

Effective hemostasis at 12 hours after andexanet administration

	Patients with baseline antifactor Xa activity ≥40 ng/mL (N = 28)			Patients with baseline antifactor Xa activity ≥75 ng/mL (N = 20)
	Patients	Excellent or good hemostasis, n (%)	95% CI (%)	Patients	Excellent or good hemostasis, n (%)	95% CI (%)
All	28	22 (78.6)	59.0–91.7	20	15 (75.0)	50.9–91.3
Patients with intracranial hemorrhage	22	18 (81.8)	59.7–94.8	16	13 (81.3)	54.4–96.0
Patients with intracerebral bleeding^a	17	13 (76.5)	50.1–93.2	12	9 (75.0)	42.8–94.5

Abbreviation: CI, confidence interval.

Patients with intracerebral bleeding are a subset of patients with intracranial hemorrhage.